Avalo Therapeutics, Inc. (AVTX) stock
AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.13−0.24 (-3.26%)
Close on Nov 17, 2026Market cap $382.38MP/E –Yield –
Avalo Therapeutics cash
Cash and short-term investments held at the end of each period.
Avalo Therapeutics's cash was $472.20M at Jun 30, 2026. For fiscal 2025 it was $98.30M, down 27.0% from the year before. Over ten years it grew 16.6% a year on average. The highest annual figure on record is $134.70M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $98.30M | -27.0% |
| FY2024 | Dec 31, 2024 | $134.70M | +1684.8% |
| FY2023 | Dec 31, 2023 | $7.55M | -43.3% |
| FY2022 | Dec 31, 2022 | $13.32M | -75.7% |
| FY2021 | Dec 31, 2021 | $54.86M | +187.2% |
| FY2020 | Dec 31, 2020 | $19.11M | +412.4% |
| FY2019 | Dec 31, 2019 | $3.73M | -65.3% |
| FY2018 | Dec 31, 2018 | $10.75M | +312.5% |
| FY2017 | Dec 31, 2017 | $2.61M | -49.9% |
| FY2016 | Dec 31, 2016 | $5.20M | -75.4% |
| FY2015 | Dec 31, 2015 | $21.16M | +80.2% |
| FY2014 | Dec 31, 2014 | $11.74M | +243.2% |
| FY2013 | Dec 31, 2013 | $3.42M | -64.1% |
| FY2012 | Dec 31, 2012 | $9.52M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $472.20M | +316.8% |
| Q1 FY2026 | Mar 31, 2026 | $82.00M | -34.4% |
| Q4 FY2025 | Dec 31, 2025 | $98.30M | -27.0% |
| Q3 FY2025 | Sep 30, 2025 | $111.60M | +36.3% |
| Q2 FY2025 | Jun 30, 2025 | $113.30M | +21.3% |
| Q1 FY2025 | Mar 31, 2025 | $125.05M | +13.5% |
| Q4 FY2024 | Dec 31, 2024 | $134.70M | +1684.8% |
| Q3 FY2024 | Sep 30, 2024 | $81.86M | +704.1% |
| Q2 FY2024 | Jun 30, 2024 | $93.43M | +1381.3% |
| Q1 FY2024 | Mar 31, 2024 | $110.18M | +560.3% |
| Q4 FY2023 | Dec 31, 2023 | $7.55M | -43.3% |
| Q3 FY2023 | Sep 30, 2023 | $10.18M | -39.9% |
| Q2 FY2023 | Jun 30, 2023 | $6.31M | -43.9% |
| Q1 FY2023 | Mar 31, 2023 | $16.69M | -56.6% |
| Q4 FY2022 | Dec 31, 2022 | $13.32M | -75.7% |
| Q3 FY2022 | Sep 30, 2022 | $16.94M | -76.3% |
| Q2 FY2022 | Jun 30, 2022 | $11.25M | -72.2% |
| Q1 FY2022 | Mar 31, 2022 | $38.47M | +0.5% |
| Q4 FY2021 | Dec 31, 2021 | $54.86M | +187.2% |
| Q3 FY2021 | Sep 30, 2021 | $71.51M | +114.1% |
| Q2 FY2021 | Jun 30, 2021 | $40.44M | -10.9% |
| Q1 FY2021 | Mar 31, 2021 | $38.29M | +576.7% |
| Q4 FY2020 | Dec 31, 2020 | $19.11M | +412.4% |
| Q3 FY2020 | Sep 30, 2020 | $33.39M | +535.9% |
| Q2 FY2020 | Jun 30, 2020 | $45.39M | +383.6% |
| Q1 FY2020 | Mar 31, 2020 | $5.66M | -64.9% |
| Q4 FY2019 | Dec 31, 2019 | $3.73M | -65.3% |
| Q3 FY2019 | Sep 30, 2019 | $5.25M | -23.2% |
| Q2 FY2019 | Jun 30, 2019 | $9.39M | +330.6% |
| Q1 FY2019 | Mar 31, 2019 | $16.12M | +538.7% |
| Q4 FY2018 | Dec 31, 2018 | $10.75M | +312.5% |
| Q3 FY2018 | Sep 30, 2018 | $6.84M | -71.5% |
| Q2 FY2018 | Jun 30, 2018 | $2.18M | -60.1% |
| Q1 FY2018 | Mar 31, 2018 | $2.52M | -15.9% |
| Q4 FY2017 | Dec 31, 2017 | $2.61M | -49.9% |
| Q3 FY2017 | Sep 30, 2017 | $23.96M | +171.8% |
| Q2 FY2017 | Jun 30, 2017 | $5.46M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $5.20M | – |
| Q3 FY2016 | Sep 30, 2016 | $8.82M | – |
See a number that looks wrong?